EuCorVac-19

EuCorVac-19
Vaccine description
TargetSARS-CoV-2
Vaccine typeProtein subunit
Clinical data
Routes of
administration		Intramuscular
Identifiers
CAS Number

EuCorVac-19 is a COVID-19 vaccine candidate developed by EuBiologics Co.[2][3][4][5]

  1. ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
  2. ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". Business Wire. 21 January 2021. Retrieved 17 April 2021.
  3. ^ Moon-hee C (21 January 2021). "EuBiologics Wins Approval on Clinical Trial of COVID-19 Vaccine 'EuCOVAC-19'". Business Korea. Retrieved 17 April 2021.
  4. ^ "EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea". EuBiologics. 21 January 2021. Retrieved 17 April 2021.
  5. ^ "Firm looks to build vaccine manufacturing plant in PH". ABS-CBN News. 12 April 2021. Retrieved 17 April 2021.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.